ArticleFrontiers in oncology2025
Predictive value of the systemic inflammation grade for overall survival in patients with colorectal cancer after surgery: outperforming NLR and mGPS.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Colorectal Cancer-One Disease, Two Fires: Distinct Inflammatory Landscapes in Colon and Rectal Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- The modified Glasgow prognostic score serves as a robust predictor of unplanned readmission and 1-year mortality in lung cancer patients receiving immune checkpoint inhibitors.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate prognostic stratification remains challenging in colorectal cancer (CRC) patients after curative resection. The Systemic Inflammation Grade (SIG), integrating neutrophil-to-lymphocyte ratio (NLR) and modified Glasgow Prognostic Score (mGPS), was proposed as a composite marker to refine risk assessment. Methods: This retrospective study analyzed 263 CRC patients undergoing R0 resection (2015-2019). Preoperative NLR and mGPS were calculated, and SIG was categorized into low (0), medium (1), and high (≥2) groups. Associations between SIG and clinicopathological variables, chemotherapy compliance, and overall survival (OS) were evaluated using ROC analysis, Kaplan-Meier curves, and Cox regression. Subgroup analyses stratified by tumor location (colon vs. rectum) were performed to assess prognostic heterogeneity. Results: Higher SIG scores correlated with elevated CEA (P=0.002), advanced TNM stage (P=0.001), and reduced chemotherapy compliance (64.0% non-compliant patients had SIG≥2, P<0.001). Multivariate analysis identified SIG (HR=2.24, P<0.001), CEA, tumor differentiation, and TNM stage as independent prognostic factors. SIG demonstrated superior prognostic accuracy (AUC=0.785) compared to NLR (0.713), mGPS (0.673), and TNM staging (0.675). Kaplan-Meier analysis revealed significant survival differences across SIG groups (5-year OS: 90.9% vs. 76.4% vs. 37.0%, P<0.001) and additional stratification within TNM stages. Subgroup analysis showed consistent prognostic efficacy of SIG in both colon and rectal cancers, with no significant interaction between SIG and tumor location (P=0.309). Conclusions: SIG outperforms existing biomarkers and complements TNM staging by capturing systemic inflammation-driven risk heterogeneity. Its prognostic consistency across colon and rectal cancers supports its utility as a universal tool for postoperative risk stratification, guiding personalized adjuvant therapy and surveillance strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.